Cargando…
Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II–IVb Nasopharyngeal Carcinoma
Background and Aims: To investigate the longitudinal trend of health-related quality of life (HRQOL) from the start to the end of concurrent chemoradiotherapy and survival in patients with advanced nasopharyngeal carcinoma (NPC). Methods: A total of 145 patients with stage II–IVb NPC, who were a sub...
Autores principales: | Li, Ji-Bin, Guo, Shan-Shan, Tang, Lin-Quan, Guo, Ling, Mo, Hao-Yuan, Chen, Qiu-Yan, Mai, Hai-Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578369/ https://www.ncbi.nlm.nih.gov/pubmed/33134176 http://dx.doi.org/10.3389/fonc.2020.579292 |
Ejemplares similares
-
Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study
por: Li, Yang, et al.
Publicado: (2017) -
Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020) -
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study
por: Guo, Shan-Shan, et al.
Publicado: (2016) -
Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents
por: Yu, Zi-Kun, et al.
Publicado: (2021) -
Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial
por: Tang, Qing-Nan, et al.
Publicado: (2021)